Pankaj Arora

US Patent:

20180291374, Oct 11, 2018

Filed:

Nov 12, 2015

Appl. No.:

15/526428

Inventors:

- Boston MA, US
Connie WU - West Roxbury MA, US
Pankaj ARORA - Birmingham AL, US
Christopher NEWTON-CHEH - Lexington MA, US
Thomas J. WANG - Lexington MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C12N 15/113

Abstract:

Provided herein are methods, kits and compositions to increase ANP levels in a subject for the treatment of hypertension and/or cardiovascular diseases, comprising at least one anti-miR agent that inhibits at least one of, or a combination of miR-103, miR-105, miR-107 and/or miR-155, alone, or in combination with an inhibitor of miR-425. Anti-miR agents can be small molecules or an oligonucleotide complementary to at least part of the sequence of hsa-miR-103, hsa-miR-105, hsa-miR-107 and/or hsa-miR-155, or their respective seed sequences or.their binding site in the 3′UTR of NPPA gene. Also provided herein are methods, kits and compositions to decrease ANP levels in a subject for the treatment of low blood pressure, comprising at least one or a combination of agonists of miR-103, miR-105, miR-107 and/or miR-155, alone or in combination with a miR-425 agonist.

US Patent:

20150133521, May 14, 2015

Filed:

Jun 14, 2013

Appl. No.:

14/408189

Inventors:

- Bouston MA, US
Pankaj Arora - Chestnut Hill MA, US
Christopher Newton-Cheh - Lexington MA, US
Thomas J. Wang - Lexington MA, US

International Classification:

C12N 15/113
A61K 45/06
C12Q 1/68
A61K 31/7088

US Classification:

514 44 A, 536 245

Abstract:

The present invention relates to methods, kits and compositions to treat hypertension and other cardiovascular diseases in a subject, in particular, a method of treating or preventing a cardiovascular disease in a subject comprising administering to a subject at least one anti-miR agent to miRNA-425. In some embodiments, an anti-miR agent is a small molecule or an oligonucleotide complementary to at least part of the miR-425 of SEQ ID NO: 1, or an anti-miR complementary to at least part of the miRNA seed sequence AUGACA (SEQ ID NO: 2). Another aspect of the present invention relates to methods, kits and compositions to treat low blood pressure in a subject comprising administering a composition comprising a miR-425 agent to decrease ANP levels in the subject. Other aspects of the present invention relates to assays, methods and systems to identify a subject at risk of hypertension, or identifying a subject suitable to administration of an anti-miR-425 agent for treatment of hypertension, the assay comprising assessing if a subject is homozygous or heterozygous for the major (A) allele of rs5068 SNP, and/or assaying for levels of miR-425 and/or assaying for levels of NT-proANP and/or levels of ANP in the plasma of a subject.